Medicine and Dentistry
Surgery
100%
Hepatectomy
80%
Neoplasm
73%
Learning Curve
72%
Adjuvant Therapy
72%
Pancreaticoduodenectomy
72%
Cytoreductive Surgery
72%
Odds Ratio
62%
Overall Survival
61%
Malignant Neoplasm
58%
Adenocarcinoma
53%
Hazard Ratio
38%
Metastatic Carcinoma
36%
Gastrectomy
34%
Adjuvant Chemotherapy
32%
Propensity Score Matching
31%
Pancreas Adenocarcinoma
31%
Pancreatectomy
31%
Neuroendocrine Tumor
31%
Randomized Controlled Trial
30%
Pancreas Cancer
28%
Hyperthermic Intraperitoneal Chemotherapy
28%
Cancer
28%
Abdominal Cancer
27%
Bile
27%
Carcinoma
24%
Post-Operative Pancreatic Fistula
24%
Neoadjuvant Therapy
24%
Morphine
24%
Venous Thromboembolism
24%
Cohort Analysis
24%
Squamous Cell Carcinoma
24%
Neurinoma
24%
Platelet
24%
Foregut
24%
COVID-19
24%
Nucleic Acid
24%
Melanoma Skin Cancer
24%
Thromboprophylaxis
24%
Extrahepatic Bile Duct
24%
Rectum Cancer
24%
Glomus Tumor
24%
Cholecystectomy
24%
Liver Disease
24%
Rectum Resection
24%
Epidural Drug Administration
24%
Bilirubin
24%
Gastrointestinal Surgery
24%
Peritoneum Mesothelioma
24%
Gastroesophageal Junction
24%
Keyphrases
National Surgical Quality Improvement Program (NSQIP)
96%
Cytoreductive Surgery
96%
Learning Curve
72%
Hepatectomy
72%
Risk Factors
68%
Systemic Chemotherapy
53%
Propensity Score Matching
51%
Adjuvant Therapy
48%
Robotics
45%
Odds Ratio
40%
Postoperative Outcomes
37%
Overall Survival
34%
Hazard Ratio
34%
Bile Leak
32%
Randomized Controlled Trial
30%
Pancreaticoduodenectomy
29%
Improved Outcomes
28%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
28%
Patient Selection
28%
Confidence Interval
25%
Postoperative Pancreatic Fistula
25%
Pancreatic Resection
24%
Surgical Treatment
24%
Minimally Invasive Gastrectomy
24%
Oligometastatic
24%
Metastatic Gastric Cancer
24%
Adenocarcinoma
24%
Minimally Invasive Approach
24%
Educational Outcomes
24%
Malignancy
24%
T2N0
24%
Surgical Fellowship
24%
Programmed Death-ligand 1 Expression
24%
Black-serving Hospitals
24%
Optimal Treatment
24%
Pure Primary Squamous Cell Carcinoma
24%
Adjuvant Chemotherapy
24%
Foregut
24%
Proctectomy
24%
Melanotic Schwannoma
24%
Thromboprophylaxis
24%
Pancreatic Cancer
24%
Adenocarcinoma of the Esophagogastric Junction
24%
Neoadjuvant Therapy
24%
Metastatic Melanoma
24%
Decreased Risk
24%
Standard-of-care Chemotherapies
24%
Novelty Response
24%
Posthepatectomy Liver Failure
24%
Anti-PD-1 Therapy
24%